Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Lee430on Mar 30, 2022 4:25pm
75 Views
Post# 34560462

RE:AACR

RE:AACRCould it be the root problem is that PL is simply getting poor IR advice from whomever is advising him internally or externally?

Could the solution simply be a candid conversation with PL from Wino that was kind enough to represent us last year, he could suggest to PL some IR solutions going forward, or the many seasoned investors here could put together a hit list of suggestions for him to consider that Wino could present to him on our behalf…. Sorry for volunteering you Wino as all this is WAY above my paygrade and my frustration level is just off the charts.

Biobob wrote:
So we have AACR coming up on April 11 and Q2 around mid April and then AGM on April 10... now it's no news sub 3$ to celebrate the printing of March statements.. I guess they don't care because the Cancer data will solve everything soon I hope... with growing sales of 80M they can refinance the debenture without giving away shares, so selling here is plain stupidity even if you hate everything about the company.


<< Previous
Bullboard Posts
Next >>